Seven Australian medtech companies are being supported to accelerate their pathway into local procurement through a national capability program aimed at strengthening the adoption of homegrown medical technologies.
The companies have been selected for the 2026 cohort of the Pathway to Market Medtech Capability Uplift Program delivered by MTPConnect, Australia’s life sciences innovation accelerator. The initiative is designed to help near-market and market-ready medtech small and medium enterprises navigate the complex procurement systems used by hospitals and health services.
The selected companies are tackling a range of healthcare challenges, including infection prevention, chronic disease management, AI-enabled patient monitoring, medication safety and advanced diagnostics. The program focuses on building the capabilities required for companies to become procurement-ready, recognising that strong technology alone is not sufficient to succeed in the healthcare purchasing environment.
MTPConnect chief executive Stuart Dignam said many Australian medtech companies face significant barriers when trying to enter the local health market. The program aims to bridge that gap by providing capability assessments, practical workshops and expert insights that help companies better understand and navigate the Victorian Government procurement pathway.
The announcement was made at the Medtech Selling to Health Masterclass, a program launch event that brought together hospital clinicians, procurement leaders and health system stakeholders to share practical guidance on how medical technologies are assessed and purchased by health services. The event is being held at the Victorian Heart Hospital within the Monash Technology Precinct and hosted by Velos Accelerator.
The 2026 cohort includes companies developing technologies across a broad spectrum of medical innovation. These include lung imaging analytics company 4D Medical, women’s health diagnostics developer Arelis, pressure injury prevention specialist Lenexa Medical and infection control manufacturer Mediklean. The group also features MX3 Diagnostics, which has developed biosensor technology for rapid hydration testing; Proton Intelligence Australia, which is developing a wearable potassium-monitoring device for cardiovascular and kidney disease management; and Sadleir Laboratories, focused on safer medication delivery systems for anaesthesia and surgery.
Victoria is serving as the pilot state for the initiative, which is supported by the Victorian Government and aims to strengthen local medtech manufacturing and innovation. The program forms part of the broader Australian Medtech Manufacturing Alliance and is delivered in partnership with BioMelbourne Network. If successful, the approach could be expanded nationally to support more Australian companies in bringing locally developed technologies into health systems.